BridgeBio to Present Interim Phase 3 FORTIFY Efficacy Data at MDA Conference
BridgeBio will present interim efficacy results from its Phase 3 FORTIFY trial of BBP-418 in LGMD2I/R9 at the MDA Clinical & Scientific Conference on March 11. Four posters and an additional oral presentation by Yale collaborators will highlight assay development, clinical outcomes, and economic burden analyses.
1. Phase 3 FORTIFY Interim Efficacy Data
BridgeBio will unveil interim results showing that BBP-418 met primary efficacy endpoints in patients with LGMD2I/R9 during a late-breaking oral session scheduled for March 11 at the MDA Clinical & Scientific Conference in Orlando.
2. Additional Presentations from Academic Collaborators
Yale School of Medicine researchers will deliver an oral presentation on a high-throughput assay for measuring ribitol response on March 11 at 11:30 am ET, alongside four posters on March 10 covering clinical outcomes, treatment patterns, cost analyses, and long-term health outcomes in LGMD2I/R9.
3. Implications for Clinical Development
Meeting efficacy endpoints in the FORTIFY trial could support a registrational pathway for BBP-418 in LGMD2I/R9, with further data expected later in 2026 to inform regulatory filings and potential market launch strategies.